Results 271 to 280 of about 6,465 (327)
Some of the next articles are maybe not open access.

Imaging of alpha particles and X-rays emitted from actinium-225 and its daughter radionuclides using a perovskite structure scintillator: YAP(Ce) based radiation imaging detector

Journal of Instrumentation
Actinium-225 (Ac-225) holds substantial promise as an alpha emitter for targeted radionuclide therapy, yet precise, energy-resolved imaging of its alpha particles and X-rays has been a challenge.
S. Yamamoto   +6 more
semanticscholar   +1 more source

Trajectory shapes of alpha particles in GAGG scintillator emitted from actinium-225 and its daughter radionuclides and application for non-proportionality estimation

Journal of Instrumentation
Although alpha particles exhibit a Bragg peak at the end of their range, it remains unclear whether this peak is accurately observed in scintillators due to their non-proportional response to alpha particles.
S. Yamamoto   +6 more
semanticscholar   +1 more source

Actinium-225 photonuclear production in nuclear reactors using a mixed radium-226 and gadolinium-157 target.

Nuclear Medicine and Biology
BACKGROUND Actinium-225 is one of the most promising radionuclides for targeted alpha therapy. Its limited availability significantly restricts clinical trials and potential applications of 225Ac-based radiopharmaceuticals.
Artem V. Matyskin   +5 more
semanticscholar   +1 more source

Chemistry of actinium — II Stability constants of thiocyanate complexes of actinium and lanthanum

Inorganic and Nuclear Chemistry Letters, 1968
Abstract The stability constants of chloride, bromide, nitrate and sulphate complexes of Ac3+ ion were reported recently (1). The present work concerns the determination of the stability constants of the thiocyanate complexes of Ac3+ ion as well as of La3+ ion in a solution of unit ionic strength and pH 2.0 at 27°C.
C.L. Rao, C.J. Shahani, K.A. Mathew
openaire   +1 more source

PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.

Journal of Clinical Oncology
5070 Background: Prostate-specific membrane antigen (PSMA) is a validated therapeutic target in mCRPC. 225Ac-J591, an alpha-emitting radionuclide linked to an anti-PSMA antibody, has been studied in several early phase clinical trials.
Valentina Marulanda Corzo   +15 more
semanticscholar   +1 more source

Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer

Physics in Medicine and Biology
Objectives. The aim of this work is to evaluate energy deposition in the nucleus and cytoplasm in targeted alpha therapy of metastatic castration-resistant prostate cancer by modeling two cell lines, PC3 (osteolytic) and LNCaP C4-2 (osteoblastic), for ...
Catherine Costa Oliveira-Silva   +3 more
semanticscholar   +1 more source

Actinium isotope cross sections for 226Ra(p,xn) reactions measured at low energies.

Applied Radiation and Isotopes
Cross sections for production of the medical isotope 225Ac by the 226Ra(p,2n) reaction have not previously been measured in fine steps over the relevant energy region, and no measurements are presently available in the literature for the actinium ...
D. Horn   +7 more
semanticscholar   +1 more source

From actinium to zinc

Physics World, 2019
Timed to coincide with the 150th anniversary of Dmitri Mendeleev's creation of the periodic table, Elementary: the Periodic Table Explained by James M Russell offers readers a potted account of all 118 known elements.
openaire   +1 more source

Prediction of crystal structures and superconductivity of actinium borides at high pressures

Physica Scripta
To investigate potential compounds that may emerge in actinium borides at high-pressure conditions. In this work, we carried out systematic crystal structure search procedure on the Ac-B compounds from 0 to 300 GPa conditions based on evolutionary ...
Yan-Qing Qin   +5 more
semanticscholar   +1 more source

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology
5010 Background: hK2 (encoded by the KLK2gene) is a novel target expressed on the cell surface of prostate cancer cells with restricted expression elsewhere.
M. Morris   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy